All In Biotech

Drug Trial Radar · NCT07748728

TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs

A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 18, 2026

Primary completion

Jul 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Conditions

  • Rheumatoid Arthritis (RA)

Interventions

  • TLL-018Drug

    Treatment group: TLL-018 20 mg BID in Period 1 → TLL-018 20 mg BID in Period 2

  • PlaceboDrug

    Placebo group: Placebo BID in Period 1 → TLL-018 20 mg BID in Period 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.